Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Siji Antiviral Mixture is a traditional Chinese medicine preparation used for its anti-inflammatory, antipyretic, and antiviral properties. [2, 3, 5] It is an approved over-the-counter medicine in China indicated for the treatment of upper respiratory tract infections, viral colds, and influenza, characterized by symptoms such as headache, fever, runny nose, and cough. [2, 11] The formula is a combination of eleven herbs: Houttuynia cordata, Platycodon grandiflorus, Morus alba leaf, Forsythia suspensa, Schizonepeta tenuifolia, Mentha haplocalyx, Perilla frutescens leaf, Prunus armeniaca seed, Phragmites communis rhizome, Chrysanthemum indicum flower, and Glycyrrhiza uralensis root. [2, 17] A clinical trial has evaluated its efficacy and safety in treating acute upper respiratory tract infections (common cold). [13, 19] Preclinical research suggests its mechanism of action may involve inhibiting the PERK/STAT3/NF-κB signaling pathway to reduce the inflammatory response and cellular stress caused by viral infections. [6, 8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Siji Antiviral Mixture.